Literature DB >> 14563430

Vectorial transport of bile acids in immortalized mouse bile duct cells.

Mami Kida1, Yutaka Mano, Yoshiyuki Ueno, Koju Kobayashi, Junichi Goto, Motoyasu Ishii, Toru Shimosegawa.   

Abstract

In ileal epithelial cells, apical sodium-dependent bile acid transporter (ASBT) is responsible for the uptake of bile acids from the lumen. Furthermore, ASBT is expressed in the apical plasma membrane of intrahepatic bile duct cells (BECs). Using cultured immortalized mouse intrahepatic BECs that form monolayers or cysts, vectorial transport of bile acids was studied. [3H]-taurocholic acid ([3H]-TCA) was transported through monolayers transcellularly almost exclusively from the apical to the basolateral side in a Na(+)- and a temperature-dependent manner. Transport of [3H]-TCA was inhibited by 59.3+/-18.6% in the presence of taurochenodeoxycholic acid. Uptake of lysyl fluorescein-conjugated bile acid, Cholyl-[Nepsilon-NBD]-lysine, was seen in a Na(+)- and a temperature-dependent manner from the apical side of BECs that form monolayer or cysts. Reverse transcription-polymerase chain reaction for mRNAs in the cells showed presence of mRNAs for ASBT and farnesoid X receptor (FXR), a nuclear bile acid receptor. In conclusion, intrahepatic BECs transport bile acids mainly from the apical to the basolateral side in concert with ASBT and maybe FXR in the cells.

Entities:  

Year:  2003        PMID: 14563430     DOI: 10.1016/s1386-6346(03)00201-8

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  2 in total

1.  LXR alpha transactivates mouse organic solute transporter alpha and beta via IR-1 elements shared with FXR.

Authors:  Masae Okuwaki; Tappei Takada; Yuki Iwayanagi; Saori Koh; Yoshiaki Kariya; Hiroshi Fujii; Hiroshi Suzuki
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

2.  New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice.

Authors:  Michel Fausther; Jonathan A Dranoff
Journal:  J Hepatol       Date:  2011-05-11       Impact factor: 25.083

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.